glucose, (beta-d)-isomer has been researched along with Bile Duct Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gu, Y; Li, W; Ming, Y; Xiao, L; Zheng, Z | 1 |
| Brell, J; Chak, A; Dowlati, A; Fu, P; Hoppel, CL; Ingalls, S; Ivy, P; Krishnamurthi, S; Posey, J; Ramanathan, RK; Rath, L; Remick, SC | 1 |
1 trial(s) available for glucose, (beta-d)-isomer and Bile Duct Cancer
| Article | Year |
|---|---|
Phase II and pharmacokinetic trial of rebeccamycin analog in advanced biliary cancers.
Topics: Aged; Antineoplastic Agents; Bile Duct Neoplasms; CA-19-9 Antigen; Carbazoles; Female; Fever; Gallbladder Neoplasms; Glucosides; Humans; Male; Middle Aged; Neutropenia; Survival Rate; Thrombocytopenia | 2009 |
1 other study(ies) available for glucose, (beta-d)-isomer and Bile Duct Cancer
| Article | Year |
|---|---|
Corilagin suppresses cholangiocarcinoma progression through Notch signaling pathway in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Bile Duct Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cholangiocarcinoma; Disease Progression; Gene Expression Regulation, Neoplastic; Glucosides; Humans; Hydrolyzable Tannins; In Vitro Techniques; Mice; Mice, Nude; Receptors, Notch; Signal Transduction; Transcription Factor HES-1; Xenograft Model Antitumor Assays | 2016 |